The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031. Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This is relatively cheaper than biologics. The abnormal growth of call is called cancer. Cancer is the second leading cause of death across the globe. Ma...
Report ID: 1078 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Size is predicted to expand with a 6.8% CAGR during the forecast period for 2025-2034. Inhibitors of VEGF (Vascular Endothelial Growth Factor) are a standard treatment for diabetic retinopathy, particularly in cases of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME). These medications function by targeting VEGF, a protein that promotes the formation of abnormal...
Report ID: 3088 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 160
Global Adalimumab Biosimilar Market Size is estimated to grow at the CAGR of 23.0% during the forecast period for 2025-2034. Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor (TNF), which is a soluble inflammatory cytokine, to treat autoimmune disorders. Adalimumab binds to TNF-alpha (TNF-), blocking it from activating TNF receptors, which are responsible for autoimmune disorders' inflammatory responses. Adalimum...
Report ID: 1058 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
The Etanercept Biosimilar Market Size is valued at XX Million in 2024 and is predicted to reach XX Million by the year 2034 at an 17.8% CAGR during the forecast period for 2025-2034. Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, an important inflammatory disease mediator in various articular diseases. Etanercept was the first tumour necrosis factor-alpha (TNF-α) inhibitor approved for the treatment of rhe...
Report ID: 1068 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Rituximab Biosimilar Market is expected to grow at a 12.3% CAGR during the forecast period for 2025-2034. Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the standard and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, as well as an autoimmune disorder such as Rheumatoid arthritis. Rituximab i...
Report ID: 1081 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Synthetic Lethality-based Drugs and Targets Market Size is predicted to witness a 14.5% CAGR during the forecast period for 2025-2034. Synthetic lethality refers to a genetic and cancer treatment notion in which the simultaneous dysfunction of two genes results in cell death, whereas the dysfunction of either gene alone does not have the same effect. This method is employed to create precise cancer treatments that take advantage of parti...
Report ID: 2657 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Vitamins, Minerals and Supplements CDMO Market Size is valued at USD 41.74 Bn in 2024 and is predicted to reach USD 97.60 Bn by the year 2034 at an 9.0% CAGR during the forecast period for 2025-2034. The Vitamins, Minerals, and Supplements (VMS) Contract Development and Manufacturing Organization (CDMO) market is a rapidly growing segment within the broader nutraceutical industry. VMS CDMOs provide comprehensive services for the development, m...
Report ID: 2669 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 165
Lentiviral Vector (LVV) CDMO Services Market Size is predicted to record a 9.0% CAGR during the forecast period for 2025-2034. Lentiviral vectors (LVs) CDMO Services are helpful for gene transfer in mammalian cells because they can efficiently transmit genes from one cell type to another. Lentivirus infections can incubate for a long time and persist for years in animals and humans. The onset of symptoms and initial infection could happen mont...
Report ID: 2374 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 179
High-Performance Liquid Chromatography Market Size was valued at USD 5.31 Bn in 2024 and is predicted to reach USD 8.37 Bn by 2034 at a 4.8% CAGR during the forecast period for 2025-2034. High-performance liquid chromatography allows for the separation, identification, and quantification of all components in a combination. Worldwide, businesses are working to perfect and sell high-performance liquid chromatography and all the parts and pieces ...
Report ID: 2429 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Global Next Generation Drug Conjugates Market Size was valued at USD 2.9 Bn in 2024 and is predicted to reach USD 12.1 Bn by 2034 at a 15.2% CAGR during the forecast period for 2025-2034. The next-generation drug conjugates (NGDCs) market represents a paradigm shift in cancer therapy, leveraging the synergistic potential of targeted drug delivery and enhanced therapeutic efficacy. NGDCs are a class of bioconjugates that combine cytotoxic payload...
Report ID: 2482 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Pharmaceuticals